Strass,
Everyone invests differently. The key word is invest though. The China deal won't start producing revenues until maybe 3rd-4th quarter this year, MMR won't even meet with India until this summer, and the biotech revenue, I assume, will probably come sometime after this. As of now, we can look forward to PHR growth and the start of MMR Pro revenues. How much are you looking to see in under 3 months? Hopefully enough, but like I said - everyone invests differently and I am not forcing anyone to stay invested here. I do believe we have a rare company in the OTC world with alot of connections that I'm willing to wait it out with. Bob Lorsch, Richard Gephardt, Asa Hutchinson, Hector Barreto, Buzz Aldrin, C. Rowland Hanson, Daniel Goldin, Sugar Ray Leonard, etc. At this point, from what I hear, they are working a full day, and also coordinating with China during the time they should be sleeping. There is more opportunity with revenue growth in China than anywhere else for this company - capturing that market will determine their success and I'm pretty sure they know that and have made this their priority along with starting to produce MMR Pro revenues. In the U.S. they have their niche market - small-time physicians. I thought Lorsch made it known that with Kodak this was more of an end-to-end solution that could be installed in hospitals and he is right - it can be, but their target market is still the 75% of small-time physicians that really are limited in their choices and are still hesitant to convert to EMRs.
News 
Market Data 
Discover 
AI
